PsychiatryNews.net

Psychiatry Xagena

Xagena Mappa
Medical Meeting
Reumabase.it
Farmaexplorer.it

Search results for "Smoking cessation"

Research on the genetics of smoking has focused on genes that are thought to be related to nicotine metabolism, personality traits, and regulation of emotions. According to a genetic study, publishe ...


The poor safety profile of the smoking-cessation drug Varenicline ( Chantix, Champix ) makes it unsuitable for first-line use, according to a study published in the journal PLoS One,Varenicline, which ...


Varenicline ( Chantix, Champix ), a smoking cessation medication, has been under a cloud of suspicion ever since the Canadian Medical Association Journal ( CMAJ ) published a study July 2011 reporting ...


In 2009, the FDA ( Food and Drug Administration ) issued a black box warning for Varenicline ( Champix; in Europe: Champix ) regarding neuropsychiatric events. Researchers used data from randomized c ...


Combining pharmacotherapies for tobacco-dependence treatment may increase smoking abstinence. A study has determined efficacy and safety of Varenicline and Bupropion sustained-release ( SR; combinatio ...


A systematic review and meta-analysis of observational studies has investigated the change in mental health after smoking cessation compared with continuing to smoke. Eligibility criteria were long ...


Placebo-controlled trials indicate that Cytisine, a partial agonist that binds the nicotinic acetylcholine receptor and is used for smoking cessation, almost doubles the chances of quitting at 6 month ...


Varenicline ( Chantix, Champix ) aids in smoking cessation but has also been associated with serious adverse events. The aim of a study was to determine the risks of cardiovascular and neuropsychia ...